We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose.
- Authors
Cohen, Idan; Campisi-Pfinto, Salvatore; Rozenberg, Orit; Colodner, Raul; Bar-Sela, Gil
- Abstract
Since January 2022 in Israel, high-risk populations with underlying health conditions were advised to receive a fourth dose of the BNT162b2 vaccine (Pfizer-BioNTech) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We monitored vaccine-induced immunity among oncology patients undergoing systemic anti-cancer therapy before and after the 4th-BNT162b2-dose. Three groups of patients were included in the study: those who received 3rd-BNT162b2-dose and had no breakthrough infection (control), those who received 3rd-BNT162b2-dose and had the breakthrough infection, and those who received the 4th-BNT162b2-dose and had no breakthrough infection. Anti-SARS-CoV-2 immunoglobulin-G (IgG) levels of the control group exhibited a rapid decrease over time, whereas IgG titers of patients with breakthrough-infections or patients vaccinated with the 4th-BNT162b2-dose were considerably elevated, consistent with the capacity of the second booster to induce anti-SARS-CoV-2 IgG levels. Additionally, oncology patients' humoral immune response was significantly greater after breakthrough-infection than in response to the 4th dose of BNT162b2.
- Subjects
ISRAEL; COVID-19; IMMUNOGLOBULINS; COVID-19 vaccines; VACCINE effectiveness; CANCER patients; INFECTION control; RESEARCH funding
- Publication
Oncologist, 2023, Vol 28, Issue 4, pe225
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyad003